Clinical Research Directory
Browse clinical research sites, groups, and studies.
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
Sponsor: CND Life Sciences
Summary
Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies. Primary Objectives 1. Identify which ET patients have P-SYN pathology indicative of prodromal PD 2. Predict which patients are most likely to phenoconvert to PD
Key Details
Gender
All
Age Range
50 Years - 85 Years
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2026-02-18
Completion Date
2029-02
Last Updated
2026-08-25
Healthy Volunteers
No
Locations (4)
CND Clinical Research Center
Scottsdale, Arizona, United States
Neurology One
Orlando, Florida, United States
Norton Healthcare
Louisville, Kentucky, United States
Veracity Neurosciences LLC
Memphis, Tennessee, United States